Overall, treatment with ABE and chitosan seems to exert a preventive effect on obesity-related NAFLD, as evidenced by their ability not only to alleviate ALT and AST levels in the blood but also to reduce lipid levels in the liver and improve histopathological changes associated with hepatic steatosis. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.